The National Heart, Lung, and Blood Institute is offering the SBIR Phase IIB Bridge Award to accelerate the commercialization of technologies for heart, lung, blood, and sleep disorders. This grant supports partnerships between Phase II awardees and investors/strategic partners to facilitate the transition of projects to the commercialization stage. Applicants must demonstrate secured or anticipated third-party funding equal to or greater than the NHLBI funds requested. Projects must align with the NHLBI mission and may involve preclinical or clinical technology development stages, with clinical trials being optional. Federal regulatory approval/clearance is necessary for proposed projects.
Opportunity ID: 305234
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HL-19-017 |
| Funding Opportunity Title: | NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 – Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.233 — National Center on Sleep Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 16, 2018 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jul 09, 2020 |
| Current Closing Date for Applications: | Jul 09, 2020 |
| Archive Date: | Aug 14, 2020 |
| Estimated Total Program Funding: | $5,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR/STTR Phase II projects to the commercialization stage by promoting partnerships between SBIR/STTR Phase II awardees and third-party investors and/or strategic partners. Applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NHLBI funds being requested throughout the Phase IIB Bridge Award project period. Projects proposed in response to this FOA must relate to the NHLBI mission and require eventual Federal regulatory approval/clearance. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-017.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00242202 | Jun 27, 2018 | May 24, 2020 | View | |
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00260192 | Jun 27, 2018 | Jul 09, 2020 | View |
Package 1
Mandatory forms
305234 RR_SF424_2_0-2.0.pdf
305234 PHS398_CoverPageSupplement_4_0-4.0.pdf
305234 RR_OtherProjectInfo_1_4-1.4.pdf
305234 PerformanceSite_2_0-2.0.pdf
305234 RR_KeyPersonExpanded_2_0-2.0.pdf
305234 RR_Budget_1_4-1.4.pdf
305234 PHS398_ResearchPlan_4_0-4.0.pdf
305234 SBIR_STTR_Information_1_2-1.2.pdf
Optional forms
305234 RR_SubawardBudget30_1_4-1.4.pdf
305234 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 2
Mandatory forms
305234 RR_SF424_2_0-2.0.pdf
305234 PHS398_CoverPageSupplement_5_0-5.0.pdf
305234 RR_OtherProjectInfo_1_4-1.4.pdf
305234 PerformanceSite_2_0-2.0.pdf
305234 RR_KeyPersonExpanded_2_0-2.0.pdf
305234 RR_Budget_1_4-1.4.pdf
305234 PHS398_ResearchPlan_4_0-4.0.pdf
305234 SBIR_STTR_Information_1_3-1.3.pdf
305234 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
305234 RR_SubawardBudget30_1_4-1.4.pdf
305234 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
